Your browser is no longer supported. Please, upgrade your browser.
URGN UroGen Pharma Ltd. daily Stock Chart
URGN [NASD]
UroGen Pharma Ltd.
Index- P/E- EPS (ttm)-5.79 Insider Own0.90% Shs Outstand21.16M Perf Week-6.68%
Market Cap509.77M Forward P/E- EPS next Y-4.56 Insider Trans-1.69% Shs Float19.30M Perf Month-3.69%
Income-121.50M PEG- EPS next Q-1.58 Inst Own74.60% Short Float13.67% Perf Quarter-13.90%
Sales0.02M P/S28320.47 EPS this Y-6.70% Inst Trans-4.00% Short Ratio9.36 Perf Half Y-23.75%
Book/sh7.11 P/B3.30 EPS next Y23.50% ROA-58.20% Target Price- Perf Year-31.81%
Cash/sh5.48 P/C4.28 EPS next 5Y- ROE-63.40% 52W Range13.12 - 38.03 Perf YTD-29.67%
Dividend- P/FCF- EPS past 5Y-65.20% ROI- 52W High-38.29% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low78.91% ATR1.38
Employees174 Current Ratio8.60 Sales Q/Q- Oper. Margin- RSI (14)49.12 Volatility5.83% 5.45%
OptionableYes Debt/Eq0.00 EPS Q/Q-61.10% Profit Margin- Rel Volume0.73 Prev Close24.00
ShortableYes LT Debt/Eq0.00 EarningsMay 07 BMO Payout- Avg Volume281.89K Price23.47
Recom1.90 SMA20-3.18% SMA507.56% SMA200-13.79% Volume205,249 Change-2.21%
Apr-16-20Reiterated H.C. Wainwright Buy $53 → $57
Apr-13-20Reiterated H.C. Wainwright Buy $75 → $53
Jan-09-20Initiated National Securities Neutral $37
May-30-19Initiated JP Morgan Neutral
May-29-19Initiated Goldman Neutral
Jan-29-19Initiated H.C. Wainwright Buy $82
Nov-08-18Resumed Jefferies Buy
Apr-04-18Upgrade Raymond James Mkt Perform → Outperform
Jan-02-18Initiated Ladenburg Thalmann Buy $50
Nov-15-17Reiterated Oppenheimer Outperform $32 → $51
Nov-15-17Downgrade Raymond James Outperform → Mkt Perform
May-15-20 09:01AM  UroGen Pharma Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer Business Wire
09:00AM  UroGen Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Jelmyto in Patients with Low-Grade Upper Tract Urothelial Cancer Business Wire
May-09-20 02:31PM  UroGen Pharma Ltd. (URGN) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 08:00AM  UroGen Pharma Reports First Quarter 2020 Financial Results and Recent Corporate Developments Business Wire
May-01-20 08:00AM  UroGen Pharma to Report First Quarter 2020 Financial Results On Thursday, May 7, 2020 Business Wire
Apr-30-20 09:05AM  UroGen Pharma (NASDAQ:URGN) Is In A Good Position To Deliver On Growth Plans Simply Wall St. -8.86%
Apr-21-20 12:34PM  With FDA Approvals in Hand, These 2 Biotech Stocks Are on Wall Streets Radar TipRanks
Apr-16-20 10:37AM  UroGen shares jump 10% on FDA approval of rare cancer treatment MarketWatch +5.23%
08:09AM  The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant Benzinga
Apr-15-20 06:22PM  UroGen Pharma Receives U.S. FDA Expedited Approval for Jelmyto, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer Business Wire -14.71%
Apr-06-20 08:53AM  UroGen (URGN) Looks Good: Stock Adds 8.1% in Session Zacks +9.09%
Apr-03-20 08:00AM  UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer Business Wire +8.06%
Mar-23-20 08:00AM  UroGen Pharma Promotes Key Personnel Focused on Commercial Operations and Expanded Clinical Development Business Wire +18.57%
Mar-16-20 11:45AM  Is UroGen Pharma Ltd. (NASDAQ:URGN) A Volatile Stock? Simply Wall St. -22.19%
Mar-06-20 08:00AM  UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Mar-02-20 08:00AM  UroGen Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments Business Wire
Feb-25-20 08:00AM  UroGen Pharma Announces March 2020 Investor Conference Schedule Business Wire
Feb-24-20 08:00AM  UroGen Pharma to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 2, 2020 Business Wire
Jan-30-20 08:59AM  Are Insiders Buying UroGen Pharma Ltd. (NASDAQ:URGN) Stock? Simply Wall St.
Jan-08-20 08:00AM  UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-19-19 08:00AM  UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101 Business Wire
Dec-17-19 07:36PM  Is UroGen Pharma Ltd. (URGN) A Good Stock To Buy? Insider Monkey
Dec-16-19 12:00PM  Volatility 101: Should UroGen Pharma (NASDAQ:URGN) Shares Have Dropped 29%? Simply Wall St. +5.07%
Dec-06-19 08:00AM  UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire +6.67%
Dec-01-19 03:06PM  Weekly CEO Buys Highlight GuruFocus.com
Nov-18-19 08:00AM  UroGen to Present at November 2019 Investor Conferences Business Wire
Nov-12-19 08:00AM  UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent Corporate Developments Business Wire +13.58%
07:20AM  The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat Benzinga
Nov-11-19 08:00AM  UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers Business Wire
Nov-06-19 10:16AM  We're Not Very Worried About UroGen Pharma's (NASDAQ:URGN) Cash Burn Rate Simply Wall St.
08:00AM  UroGen Pharma to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019 Business Wire
Sep-30-19 08:00AM  UroGen To Present at October 2019 Investor Conference Business Wire
Sep-24-19 04:01PM  UroGen Investor Day Details Positive Clinical Updates, UGN-101 Launch Preparedness, and Pipeline Advances Business Wire
10:25AM  UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer Business Wire
Sep-18-19 12:15PM  Does UroGen Pharma Ltd. (NASDAQ:URGN) Have A High Beta? Simply Wall St.
Sep-10-19 08:00AM  UroGen To Host Investor Day on September 24, 2019 Spotlighting Clinical Development Updates and UGN-101 Launch Readiness Business Wire
Sep-06-19 04:05PM  UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-13-19 03:05PM  Estimating The Intrinsic Value Of UroGen Pharma Ltd. (NASDAQ:URGN) Simply Wall St. +5.58%
Aug-12-19 04:23PM  UroGen Pharma Ltd. (URGN) Q2 2019 Earnings Call Transcript Motley Fool
Aug-10-19 07:11AM  3 Stocks the World's Best Investors Are Buying Right Now Motley Fool
Aug-09-19 08:00AM  UroGen Pharma Reports Second Quarter 2019 Financial Results and Recent Corporate Developments Business Wire
Aug-05-19 08:00AM  UroGen Pharma to Report Second Quarter 2019 Financial Results on Friday, August 9, 2019 Business Wire
Jul-23-19 10:43AM  Here's Why the Best Is Yet to Come for UroGen Pharma Motley Fool
Jul-16-19 09:48AM  UroGen Pharma Sees Hammer Chart Pattern: Time to Buy? Zacks
Jul-05-19 05:14PM  Hedge Funds Have Never Been This Bullish On UroGen Pharma Ltd. (URGN) Insider Monkey
Jul-01-19 08:00AM  UroGen Pharma Joins Russell 3000® Index Business Wire
May-30-19 08:00AM  UroGen Pharma to Present at June 2019 Investor Conferences Business Wire
May-26-19 08:18AM  3 Top Stocks That Aren't on Wall Street's Radar Motley Fool
May-20-19 12:48PM  These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month Motley Fool
May-09-19 01:23PM  UroGen Pharma Ltd. (URGN) Q1 2019 Earnings Call Transcript Motley Fool
08:00AM  UroGen Pharma Reports First Quarter 2019 Financial Results and Recent Corporate Developments Business Wire
May-07-19 12:53PM  Is UroGen Pharma Ltd. (URGN) A Good Stock To Buy? Insider Monkey
May-06-19 11:00AM  What Are Analysts Saying About UroGen Pharma Ltd.'s (NASDAQ:URGN) Earnings Outlook? Simply Wall St.
May-05-19 04:25PM  UroGen Delivers Updated Complete Response (CR) and Durability Data from the UGN-101 Phase 3 OLYMPUS Trial Business Wire
May-02-19 08:00AM  UroGen Pharma to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019 Business Wire
Apr-23-19 08:00AM  UroGen Pharma Announces Early Stage Feasibility Agreement with Janssen Business Wire
Apr-20-19 07:02PM  3 International Companies Making Waves in the U.S. Soon Motley Fool
Apr-16-19 10:21AM  1 Under-the-Radar Healthcare Stock Wall Street Is Overlooking Motley Fool
Apr-05-19 09:12AM  UroGen Pharma Announces Presentation of Analysis from Phase 3 OLYMPUS Trial of UGN-101 for Patients with Low-Grade Upper Tract Urothelial Cancer Business Wire
Mar-25-19 02:39PM  What Type Of Shareholder Owns UroGen Pharma Ltd.s (NASDAQ:URGN)? Simply Wall St.
Mar-05-19 08:00AM  UroGen Pharma to Present at March 2019 Investor Conferences Business Wire
Feb-28-19 11:37AM  UroGen Pharma Ltd. (URGN) Q4 2018 Earnings Conference Call Transcript Motley Fool
08:00AM  UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results Business Wire
Feb-21-19 08:00AM  UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 28, 2019 Business Wire
Feb-19-19 08:15AM  Factors of Influence in 2019, Key Indicators and Opportunity within Toyota Motor, UROGEN PHARMA, Macerich, Cosan, Middlesex Water, and Howard Hughes New Research Emphasizes Economic Growth GlobeNewswire
Feb-06-19 12:00PM  What Investors Should Know About UroGen Pharma Ltd.s (NASDAQ:URGN) Financial Strength Simply Wall St.
Jan-29-19 02:17PM  Don't Waste Your Money on Penny Stocks. These 3 Stocks Are Better Buys Motley Fool
Jan-28-19 04:05PM  UroGen Pharma Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares Business Wire -5.51%
Jan-24-19 12:26PM  Here's Why Urogen Pharma Fell as Much as 12.4% Today Motley Fool -7.47%
07:45AM  The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial Benzinga
Jan-23-19 10:16PM  UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares Business Wire -14.41%
07:22AM  The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study Benzinga
Jan-22-19 04:01PM  UroGen Pharma Announces Proposed Public Offering of Ordinary Shares Business Wire
Jan-08-19 08:00AM  UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Business Wire -5.87%
Jan-03-19 06:30AM  UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer Business Wire +6.87%
Dec-22-18 12:36AM  Is UroGen Pharma Ltd. (URGN) A Good Stock To Buy? Insider Monkey
Dec-20-18 10:07AM  How Many Insiders Sold UroGen Pharma Ltd. (NASDAQ:URGN) Shares? Simply Wall St.
Dec-17-18 08:00AM  UroGen Pharma Initiates Rolling Submission of New Drug Application (NDA) for UGN-101 for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Business Wire
Dec-03-18 07:25AM  Market Trends Toward New Normal in Zillow Group, YRC Worldwide, The Home Depot, UROGEN PHARMA, ZIOPHARM Oncology, and Cinedigm Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-12-18 08:00AM  UroGen Pharma Reports Third Quarter 2018 Financial Results and Completed UGN-101 OLYMPUS Trial Enrollment Business Wire
Nov-06-18 08:00AM  UroGen Pharma to Present at November 2018 Investor Conferences Business Wire
Nov-05-18 08:00AM  UroGen Pharma to Report Third Quarter 2018 Financial Results on Monday, November 12, 2018 Business Wire
Oct-30-18 08:00AM  FDA Grants Breakthrough Therapy Designation (BTD) for UroGen Pharmas UGN-101 for the Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Business Wire
Oct-24-18 08:50AM  Market Trends Toward New Normal in UROGEN PHARMA, Cimarex Energy, Boingo Wireless, TransCanada, EXTRACTION O&G, and ACADIA Pharmaceuticals Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire -5.82%
Oct-05-18 03:35PM  Shareholders Should Check The Ownership Structure Of UroGen Pharma Ltd (NASDAQ:URGN) Simply Wall St.
Sep-25-18 08:00AM  UroGen Pharma to Present at the Ladenburg Thalmann 2018 Healthcare Conference Business Wire
Sep-11-18 08:00AM  Jones Woody Bryan Joins UroGen Pharma as Senior Vice President of Business Development Business Wire +6.24%
Aug-14-18 07:00AM  UroGen Pharma Reports Second Quarter 2018 Financial Results and Recent Corporate Developments GlobeNewswire
06:30AM  UroGen Pharma Ltd. to Host Earnings Call ACCESSWIRE
Aug-08-18 08:00AM  UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer GlobeNewswire
Aug-07-18 08:00AM  UroGen Pharma to Report Second Quarter 2018 Financial Results on Tuesday, August 14, 2018 GlobeNewswire
Jul-11-18 08:00AM  UroGen Pharma Submits Investigational New Drug (IND) Application for UGN-102 (VesiGel) for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC) GlobeNewswire
Jul-10-18 08:00AM  UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors GlobeNewswire
Jun-13-18 08:00AM  UroGen Pharmas Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award GlobeNewswire
Jun-06-18 07:30AM  Investor Expectations to Drive Momentum within Mesoblast, Access National, Urogen Pharma, TechTarget, Sina, and CoStar Group Discovering Underlying Factors of Influence GlobeNewswire
Jun-05-18 08:00AM  UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance GlobeNewswire
May-29-18 08:00AM  UroGen Pharma to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-21-18 01:40PM  UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC) GlobeNewswire
May-16-18 11:50AM  Urogen Pharma Ltd. (URGN) Q1 2018 Earnings Conference Call Transcript Motley Fool
May-15-18 08:00AM  UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments GlobeNewswire
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; and Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery. UroGen Pharma Ltd. was founded in 2004 and is based in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PFREUNDSCHUH PETER P.Chief Financial OfficerMay 20Sale25.073588,9757,079May 20 04:44 PM
Barrett Elizabeth A.Chief Executive OfficerMay 12Option Exercise0.0035,2290157,465May 14 01:07 PM
Schoenberg MarkChief Medical OfficerApr 27Sale24.35701,70517,711Apr 28 01:53 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerApr 27Sale24.351413,4336,396Apr 28 01:51 PM
Mullennix StephenChief Operating OfficerApr 27Sale24.351453,53110,084Apr 28 01:43 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerFeb 20Sale29.6836010,6856,120Feb 24 04:53 PM
Mullennix StephenChief Operating OfficerFeb 14Sale28.0461217,1609,812Feb 18 02:33 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerJan 27Sale29.2866719,5304,438Jan 28 05:15 PM
Mullennix StephenChief Operating OfficerJan 27Sale29.2668420,0148,665Jan 28 05:14 PM
Schoenberg MarkChief Medical OfficerJan 27Sale29.153229,3869,177Jan 28 05:10 PM
Barrett Elizabeth A.Chief Executive OfficerJan 03Option Exercise0.00105,6880122,236Jan 07 06:30 PM
Barrett Elizabeth A.Chief Executive OfficerNov 21Buy28.007,530210,84016,548Nov 22 03:34 PM
Barrett Elizabeth A.Chief Executive OfficerNov 20Buy28.007,470209,1609,018Nov 22 01:35 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerNov 20Sale28.4135410,0573,439Nov 22 01:29 PM
Schoenberg MarkChief Medical OfficerNov 19Buy28.171,96055,2137,967Nov 21 08:49 PM
Barrett Elizabeth A.Chief Executive OfficerNov 15Buy26.001,54840,2481,548Nov 18 07:32 PM
Mullennix StephenChief Operating OfficerNov 14Sale26.0060815,8067,683Nov 18 04:04 PM